Home · Stock · LLY

LLY Eli Lilly & Co

Which ETFs hold LLY? Eli Lilly & Co is held by 6 funds tracked by ETFpeek.

Held by 6 funds todayData as of 9 Oct 2026
HealthcareDrug Manufacturers - General
$1,170
+41.2% 1y
$783.8552-week range$1,293
Market cap
$1.0T
P/E
39.3
Dividend
0.59%
3-month
-1.5%
CEO
Mr. David A. Ricks
Revenue · last 4 qtrs (+47.7% YoY)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Provider

Currently Held By

ARK
ARKG
ARK Genomic Revolution ETF
Weight in fund3.73%
Shares held65,296
Market value$76.4M
View fund →
VANGUARD
VUG
Weight in fund2.64%
Shares held8,797,947
Market value$10.18B
View fund →
SMARTSHARES
USG
Smart US Large Growth ETF
via VUG
Weight in fund2.64%
Shares held—
Market value$16.9M NZD
View fund →
VANGUARD
VOO
Weight in fund1.38%
Shares held21,016,458
Market value$24.31B
View fund →
SMARTSHARES
USF
Smart US 500 ETF
via VOO
Weight in fund1.38%
Shares held—
Market value$17.3M NZD
View fund →
ARK
ARKK
ARK Innovation ETF
Weight in fund0.48%
Shares held28,128
Market value$32.9M
View fund →
Not held by the selected provider.
last 90 days
Net flow (90d):−$8.7M (1 without value)·9 BUY / 3 SELL·score ≥ 40
DatePersonActionPlanSharesValueScore i
10 Aug 2026
Donald A Zakrowski
Senior VP of Finance & Chief Accounting Officer
SELLUnknown2,000$2.4M90
7 Aug 2026
Anat Hakim
Executive VP, General Counsel & Secretary
SELLUnknown5,000$6.0M70
Net flow (90d):−$8.7M (1 without value)·9 BUY / 3 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
21 Sep 2026
Juan R Luciano
Director / Other
BUYVested (RSU)14$16K30
21 Sep 2026
J Erik Fyrwald
Director / Other
BUYVested (RSU)9$10K30
21 Sep 2026
Ralph Alvarez
Director / Other
BUYVested (RSU)11$13K30
21 Sep 2026
Gabrielle Sulzberger
Director / Other
BUYVested (RSU)4$5K30
10 Aug 2026
Donald A Zakrowski
Senior VP of Finance & Chief Accounting Officer
SELLUnknown2,000$2.4M90
7 Aug 2026
Anat Hakim
Executive VP, General Counsel & Secretary
SELLUnknown5,000$6.0M70
1 Aug 2026
Melissa Seymour
Director / Other
BUYOption Exercise981—30
1 Aug 2026
Melissa Seymour
Director / Other
SELLVested (RSU)439$504K30
20 Jul 2026
Juan R Luciano
Director / Other
BUYVested (RSU)14$16K30
20 Jul 2026
J Erik Fyrwald
Director / Other
BUYVested (RSU)9$10K30
20 Jul 2026
Ralph Alvarez
Director / Other
BUYVested (RSU)11$13K30
20 Jul 2026
Gabrielle Sulzberger
Director / Other
BUYVested (RSU)4$5K30
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
9 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
21 Jul 2026ARKGBUYAdded+2,731+0.25%4.24%
9 Jul 2026ARKGBUYAdded+14,638+1.05%24.19%
8 Jul 2026ARKGBUYAdded+6,354+0.60%13.72%
26 Jun 2026ARKGBUYAdded+713-0.03%1.81%
25 Jun 2026ARKGBUYAdded+7,292+0.41%19.59%
22 Jun 2026ARKKBUYAdded+2,480+0.03%8.09%
22 Jun 2026ARKGBUYAdded+6,039+0.35%20.13%
18 Jun 2026ARKKBUYNew position+28,952+0.47%100.00%
18 Jun 2026ARKGBUYAdded+12,184+0.99%51.04%
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds